| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Monday’s Close |
|---|---|---|---|---|---|
| AZN | Astrazeneca PLC | $37.56 | $95.16B | N/A |
Pharma Stock Roundup: PFE to Buy ARRY, RHHBY, MRK, AZN Drugs Get Regulatory Nod
http://www.zacks.com/stock/news/432688/pharma-stock-roundup-pfe-to-buy-arry-rhhby-mrk-azn-drugs-get-regulatory-nod?cid=CS-ZC-FT-432688
Jun 21, 2019 - Pfizer (PFE) announces definitive deal buy Array BioPharma. Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) win approvals for new drugs/line extensions.
0
AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use
http://www.zacks.com/stock/news/431009/astrazeneca-mercks-lynparza-wins-eu-nod-for-first-line-use?cid=CS-ZC-FT-431009
Jun 18, 2019 - AstraZeneca (AZN) and Merck's PARP inhibitor, Lynparza, gets approval in EU as a front-line therapy for BRCA-mutated advanced ovarian cancer.
0
AstraZeneca Gives Detailed Data From Calquence Leukemia Study
http://www.zacks.com/stock/news/430525/astrazeneca-gives-detailed-data-from-calquence-leukemia-study?cid=CS-ZC-FT-430525
Jun 17, 2019 - AstraZeneca's (AZN) Calquence monotherapy prolongs progression-free survival significantly in relapsed or refractory CLL patients compared to Roche's Rituxan.
0
Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod
http://www.zacks.com/stock/news/429560/pharma-stock-roundup-mrk-buys-small-cancer-biotech-rhhby-mrk-drugs-get-fda-nod?cid=CS-ZC-FT-429560
Jun 14, 2019 - Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.
0
Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache
http://www.zacks.com/stock/news/426292/pharma-stock-roundup-asco-update-fda-nod-for-llys-emgality-for-cluster-headache?cid=CS-ZC-FT-426292
Jun 07, 2019 - Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.
0
Was ASCO Quieter for Big Drug/Biotech Stocks This Year?
http://www.zacks.com/stock/news/425444/was-asco-quieter-for-big-drug-biotech-stocks-this-year?cid=CS-ZC-FT-425444
Jun 06, 2019 - The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.
0
Ironwood Initiates Dosing in Mid-Stage Study for MD-7246
http://www.zacks.com/stock/news/425026/ironwood-initiates-dosing-in-mid-stage-study-for-md-7246?cid=CS-ZC-FT-425026
Jun 05, 2019 - Ironwood (IRWD)and its partner initiate dosing in a phase II study evaluating delayed-release version of Linzess, MD-7246, in patients with IBS-D.
0
Glaxo's Nucala Gets CHMP Nod for 2 Self-Administered Options
http://www.zacks.com/stock/news/424909/glaxos-nucala-gets-chmp-nod-for-2-self-administered-options?cid=CS-ZC-FT-424909
Jun 05, 2019 - GlaxoSmithKline (GSK) announces that the EMA???s Committee for Medicinal Products for Human Use has issued a positive opinion for two self-administered options of its asthma drug, Nucala.
0
Why Cancer-Fighting Stocks & ETFs Are Soaring
http://www.zacks.com/stock/news/424108/why-cancer-fighting-stocks-etfs-are-soaring?cid=CS-ZC-FT-424108
Jun 03, 2019 - The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.
0
AstraZeneca's Imfinzi Shows Long-Term Benefits in Lung Cancer
http://www.zacks.com/stock/news/423951/astrazenecas-imfinzi-shows-long-term-benefits-in-lung-cancer?cid=CS-ZC-FT-423951
Jun 03, 2019 - AstraZeneca (AZN) presents follow-up data on Imfinzi from late-stage PACIFIC study evaluating it in lung cancer patients.
0
Page 1>